Skip to main content
SpringerLink
Log in

Cytokine-Induced Vascular Leak Syndrome

  • Protocol
Cytokines in Human Health

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

The vascular leak syndrome (VLS) is a major dose-limiting toxicity of cytokine therapy. VLS is characterized by an increase in vascular permeability resulting in tissue edema and, ultimately, multiple organ failure. The most frequent clinical manifestations of cytokine-induced VLS include weight gain, edema, oliguria, hypotension, and dyspnea. Respiratory insufficiency requiring mechanical ventilation and hypotension requiring pressor support have been described as the most severe manifestations of VLS. The pathogenesis of vascular damage is complex and can involve activation of endothelial cells and leukocytes, release of cytokine and inflammatory mediators, and alterations in cell-cell and cell-matrix adhesion with disturbance of vascular integrity. A better understanding of these mechanisms may lead to the development of interventions that will improve the therapeutic efficacy of cytokines. This chapter discusses the clinical manifestation, possible mechanisms, and therapeutic modalities for VLS induced by cytokine therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lotze MT, Raynor AA, Ettinghausen SE, Vetto JT, Scipp CA, Rosenberg SA. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986;58: 2764–2772.

    CAS  PubMed  Google Scholar 

  2. Rosenberg SA, Lotze MT, Muul, LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316: 889–897.

    CAS  PubMed  Google Scholar 

  3. Glauser FL, DeBlois G, Bechard D, Fowler AA, Merchant R, Fairman RP. Cardiopulmonary toxicity of adoptive immunotherapy. Am J Med Sci 1988; 296:406–412.

    CAS  PubMed  Google Scholar 

  4. Chang AE, Rosenberg SA. Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol 1989;5:385–390.

    CAS  PubMed  Google Scholar 

  5. West WH. Clinical application of continuous infusion of recombinant interleukin-2. Eur J Cancer Clin Oncol 1989;25:S11–S15.

    PubMed  Google Scholar 

  6. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Safety 1992;7:417–433.

    CAS  PubMed  Google Scholar 

  7. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992;46:473–484.

    CAS  PubMed  Google Scholar 

  8. Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Safety 1995:13:371–406.

    CAS  PubMed  Google Scholar 

  9. Vial T, Descotes J, Immune-mediated side-effects of cytokines in humans. Toxicology 1995; 105:31–57.

    CAS  PubMed  Google Scholar 

  10. Baluna R, Viteta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997;37:117–132.

    CAS  PubMed  Google Scholar 

  11. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 2000;6(Suppl 1):S2–S7.

    PubMed  Google Scholar 

  12. Worth LL, Jaffe N, Benjamin RS, et al. Phase II study of recombinant interleukinl alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res 1997;3:1721–1729.

    CAS  PubMed  Google Scholar 

  13. Hurwitz N, Probst A, Zufferey G, et al. Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. Leuk Lymphoma 1996;20; 337–340.

    CAS  PubMed  Google Scholar 

  14. Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol 1994;5:447–452.

    CAS  PubMed  Google Scholar 

  15. Atkins MB, Vachino G, Tilg HJ, et al. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol 1992;10:1802–1809.

    CAS  PubMed  Google Scholar 

  16. Yamamoto K, Mizuno M, Tsuji T, Amano T. Capillary leak syndrome after interferon treatment for chronic hepatitis C. Arch Intern Med 2002; 162:481–482.

    PubMed  Google Scholar 

  17. Schmidt S, Hertfelder HJ, von Spiegel T. Lethal capillary leak syndrome after a single administration of interferon beta-lb. Neurology 1999;53:220–222.

    CAS  PubMed  Google Scholar 

  18. Sculier JP, Bron D, Verboven N, Klastersky J. Multiple organ failure during interleukin-2 administration and LAK cells infusion. Intensive Care Med 1988; 14:666–667.

    CAS  PubMed  Google Scholar 

  19. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokineactivated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486–498.

    CAS  PubMed  Google Scholar 

  20. Dutcher JP, Gaynor ER, Boldt DH, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641–648.

    CAS  PubMed  Google Scholar 

  21. Philip T, Mercatello A, Negrier S, et al. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. Cancer Treat Rev 1989;16:91–104.

    PubMed  Google Scholar 

  22. Lindenman A, Hoffken K, Schmidt RE, et al. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989;28:275–281.

    Google Scholar 

  23. Wersall JP, Masucci G, Hjelm AL, et al. Low dose cyclophosphamide, alphainterferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma. Med Oncol Tumor Pharmacother 1993; 10:103–111.

    CAS  PubMed  Google Scholar 

  24. Hamblin TJ, Sadullah S, Williamson P, et al. A phase-Ill study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. Br J Cancer 1993;68:1186–1189.

    CAS  PubMed  Google Scholar 

  25. Emminger W, Emminger-Schmidmeier W, Peters C, et al. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blutalkohol 1990;61:219–221.

    CAS  Google Scholar 

  26. Rechner I, Brito-Babapulle F, Fielden J. Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF). Hematol J 2003;4:54–56.

    PubMed  Google Scholar 

  27. Bajorin DF, Chapman PB, Wong G, et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990;50:7490–7495.

    CAS  PubMed  Google Scholar 

  28. Mackie FE, Umetsu D, Salvatierra O, Sarwal MM. Pulmonary capillary leak syndrome with intravenous cyclosporin A in pediatrie renal transplantation. Pediatr Transplant 2000;4:35–38.

    CAS  PubMed  Google Scholar 

  29. Carlson K, Smedmyr B, Hagberg H, Oberg G, Simonsson B. Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide)±TBI and autologous BMT for malignant lymphomas. Bone Marrow Transplant 1993; 11:205–208.

    CAS  PubMed  Google Scholar 

  30. Beckerbauer L, Tepe JJ, Eastman RA, Mixter PF, Williams RM, Reeves R. Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome. ChemBiol 2002;9:427–441.

    CAS  Google Scholar 

  31. De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 2001;12: 1651–1652.

    PubMed  Google Scholar 

  32. Pulkkanen K, Kataja V, Johansson R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemotherapy 2003;15:287–289.

    CAS  Google Scholar 

  33. Semb KA. Aamdal S. Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16:3426–3432.

    CAS  PubMed  Google Scholar 

  34. Woods WG, Ramsay NK, Weisdorf DJ, et al. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: Lack of superiority over cyclophosphamide-containing conditioning regimens. Bone Marrow Transplant 1990;6:9–16.

    CAS  PubMed  Google Scholar 

  35. Estival JL, Dupin M, Kanitakis J, Combemale P. Capillary leak syndrome induced by acitretin. Br J Dermatol 2004;150:150–152.

    CAS  PubMed  Google Scholar 

  36. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: Magic bullets or misguided missiles. Immunol. Today 1993; 14:252–259.

    CAS  PubMed  Google Scholar 

  37. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin, IgG-RFB4-SMPT-dgA in patients with B cell lymphoma: a phase I study. Blood 1995;85:3457–3465.

    CAS  PubMed  Google Scholar 

  38. Frankel AE, Tagge EP, Willingham MC. Clinical trials of targeted toxins. Semin Cancer Biol 1995;6:307–317.

    CAS  PubMed  Google Scholar 

  39. Funke I, Prummer O, Schrezenmeier H, et al. Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. Ann Hematol 1994;68:49–52.

    CAS  PubMed  Google Scholar 

  40. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003;17:1150–1156.

    CAS  PubMed  Google Scholar 

  41. Dereure O, Portales P, Clot J, Guilhou JJ. Biclonal Sezary syndrome with capillary leak syndrome. Dermatology 1994;188:152–156.

    CAS  PubMed  Google Scholar 

  42. Jillella AP, Day DS, Severson K, Kallab AM, Burgess R. Non-Hodgkin’s lymphoma presenting as anasarca: probably mediated by tumor necrosis factor alpha (TNF-alpha). Leuk Lymphoma 2000;38:419–422.

    CAS  PubMed  Google Scholar 

  43. Margarson MP, Soni NC. Changes in serum albumin concentration and volume expanding effects following a bolus of albumin 20% in septic patients. Br J Anaesth 2004;92:821–826.

    CAS  PubMed  Google Scholar 

  44. Teelucksingh S, Padfield PL, Edwards CR. Systemic capillary leak syndrome. Q J Med 1990;75:515–524.

    CAS  PubMed  Google Scholar 

  45. Nelson BK. Snake envenomation. Incidence, clinical presentation and management. Med Toxicol Adverse Drug Exp 1989;4:17–31.

    CAS  PubMed  Google Scholar 

  46. Benedetti TJ, Kates R, Williams V. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema. Am J Obstet Gynecol 1985; 152:330–334.

    CAS  PubMed  Google Scholar 

  47. Atkinson JP, Waldmann TA, Stein SF, et al. Systemic capillary leak syndrome and monoclonal IgG gammopathy: studies in a sixth patient and a review of the literature. Medicine 1977;56:225–239.

    CAS  PubMed  Google Scholar 

  48. Barnadas MA, Cistero A, Sitjas D, Pascual E, Puig X, de Moragas JM. Systemic capillary leak syndrome. J Am Acad Dermatol 1995;32:364–366.

    CAS  PubMed  Google Scholar 

  49. Zhang W, Ewan PW, Lachmann PJ. The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol 1993;93:424–429.

    CAS  PubMed  Google Scholar 

  50. Zikria BA. Mechanisms of multiple system organ failure. In: Zikria BA, Oz MO, Carlson RW, eds. Reperfusion Injuries and Clinical Capillary Leak Syndrome. Armonk, NY: Futura Publishing Co.; 1994, pp. 443–489.

    Google Scholar 

  51. Abramov Y, Galun E, Granat M, et al. Postpartum systemic capillary leak syndrome: A possible etiology. Acta Obstet Gynecol Scand 1995;74:395–398.

    CAS  PubMed  Google Scholar 

  52. McGregor JM, Barker JN, MacDonald DM. Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: possible role of cytokines. Br J Dermatol 1991; 125:472–474.

    CAS  PubMed  Google Scholar 

  53. Karne S. Gorelick FS. Etiopathogenesis of acute pancreatitis. Surg Clin North Am 1999;79:699–710.

    CAS  PubMed  Google Scholar 

  54. Tassani P, Schad H, Winkler C, et al. Capillary leak syndrome after cardiopulmonary bypass in elective, uncomplicated coronary artery bypass grafting operations: does it exist? J Thorac Cardiovasc Surg 2002;123:735–741.

    CAS  PubMed  Google Scholar 

  55. Fishel RS, Are C, Barbul A. Vessel injury and capillary leak. Crit Care Med 2003;31(8 Suppl):S502–S511.

    PubMed  Google Scholar 

  56. Ettinghausen SE, Puri RK, Rosenberg SA. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 1988;80: 177–188.

    CAS  PubMed  Google Scholar 

  57. Vitetta ES, Stone M, Amlot P, et al. A phase I immunotoxin trial in patients with B cell lymphoma. Cancer Res 1991;51:4052–4058.

    CAS  PubMed  Google Scholar 

  58. Dolberg-Stolik OC, Putterman C, Rubinow A, Rivkind AI, Sprung CL. Idiopathic capillary leak syndrome complicated by massive rhabdomyolysis. Chest 1993;104:123–126.

    CAS  PubMed  Google Scholar 

  59. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of vascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986;137:1735–1742.

    CAS  PubMed  Google Scholar 

  60. Pichert G, Jost LM, Fierz W, Stahel RA. Clinical and immune modulatory effects of alternative weekly IL-2 and interferon-2a in patients with advanced renal cell carcinoma and melanoma. Br J Cancer 1991;63:287–292.

    CAS  PubMed  Google Scholar 

  61. Textor SC, Margolin K, Blayney D, Carlson J, Doroshow J. Renal, volume and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. Am J Med 1987;83:1055–1061.

    CAS  PubMed  Google Scholar 

  62. Stahel RA, Sculier JP, Jost LM, et al. Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2) [ala] 125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol 1989;25:965–972.

    CAS  PubMed  Google Scholar 

  63. van Haelst Pisani C, Kovach JS, Kita H, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991;78:1538–1544.

    PubMed  Google Scholar 

  64. Gately MK, Anderson TD, Hayes TJ. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol 1988;141:189–200.

    CAS  PubMed  Google Scholar 

  65. Droder RM, Kyle RA, Greipp PR. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med. 1992;92:523–526.

    CAS  PubMed  Google Scholar 

  66. Vogelzang PJ, Droder RM, Kyle RA, Greipp PR. Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters. Chest 1992;101:746–752.

    CAS  PubMed  Google Scholar 

  67. O’Hearn DJ, Leiferman KM, Askin F, Georas SN. Pulmonary infiltrates after cytokine therapy for stem cell transplantation. Massive deposition of eosinophil major basic protein detected by immunohistochemistry. Ame J Respi Crit Care Med 1999;160:1361–1365.

    CAS  Google Scholar 

  68. Mann H, Ward JH, Samlowski. Vascular leak syndrome associated with interleukin-2: Chest radiographic manifestations. Radiology 1990; 176:191–194.

    CAS  PubMed  Google Scholar 

  69. Conant EF, Fox KR, Miller WT. Pulmonary edema as a complication of interleukin-2 therapy. Am J Roentgenol 1989; 152:749–752.

    CAS  Google Scholar 

  70. Briasoulis E, Pavlidis N. Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy. Oncologist 2001;6:153–161.

    CAS  PubMed  Google Scholar 

  71. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001;24:287–293.

    CAS  PubMed  Google Scholar 

  72. Lee RE, Lotze MT, Skibber JM. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;7:7–20.

    CAS  PubMed  Google Scholar 

  73. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998;83:797–805.

    CAS  PubMed  Google Scholar 

  74. Ketai LH, Goodwin JD. A new view of pulmonary edema and acute respiratory distress syndrome: state of the art. J Thorac Imaging 1998;13:147–171.

    CAS  PubMed  Google Scholar 

  75. Sonntag J, Grunert U, Stover B, Obladen M. [The clinical relevance of subcutaneous-thoracic ratio in preterm newborns as a possibility for quantification of capillary leak syndrome], Zeitschrift fur Geburtshilfe und Neonatologie 2003;207:208–212.

    CAS  PubMed  Google Scholar 

  76. Gaynor ER, Vitek L, Sticklin L, et al. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1988; 109:953–958.

    CAS  PubMed  Google Scholar 

  77. Guleria AS, Yang JC, Topalian SL. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. J Clin Oncol 1994;12:2714–2722.

    CAS  PubMed  Google Scholar 

  78. Bechard DE, Gudas SA, Sholley M, et al. Nonspecific cytotoxicity of recombinant interleukin-2 activated lymphocytes. Am J Med Sci 1989;298:28–33.

    CAS  PubMed  Google Scholar 

  79. Edwards MJ, Miller FN, Sims DE, Abney DL, Schuschke DA, Corey TS. Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage. Cancer Res 1992;52:3425–3431.

    CAS  PubMed  Google Scholar 

  80. Navarro C, Garcia-Bragado F, Lima J, Fernandez JM. Muscle biopsy findings in systemic capillary leak syndrome. Hum Pathol 1990;21:297–301.

    CAS  PubMed  Google Scholar 

  81. Fujita S, Puri RK, Yu ZX, Travis WD, Ferrans VJ. An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer 1991; 68:2169–2174.

    CAS  PubMed  Google Scholar 

  82. Queluz TT, Brunda M, Vladutiu AO, Brentjens JR, Andres G. Morphological basis of pulmonary edema in mice with cytokine-induced vascular leak syndrome. Exp Lung Res 1991;17:1095–1108.

    CAS  PubMed  Google Scholar 

  83. Downie Ryan US, Hayes BA, Friedman M. Interleukine-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro. Am J Respir Cell Mol Biol 1992;7:58–65.

    Google Scholar 

  84. Dinarello CA. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 1991; 163: 1177–1184.

    CAS  PubMed  Google Scholar 

  85. Campbell WN, Ding X, Goldblum SE. Interleukin-la and-β augment pulmonary artery transendothelial albumin flux in vitro. Am J Physiol 1992;263: L128–L136.

    CAS  PubMed  Google Scholar 

  86. Maruta MK, Burkart V, Gillis S, Kolb H. IL-1 and IFN-increase vascular permeability. Immunology 1988;64:301–305.

    PubMed  Google Scholar 

  87. Baluna R, Rizo J, Gordon BE, Ghetie V. Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999;96:3957–3962.

    CAS  PubMed  Google Scholar 

  88. Baluna R, Coleman E, Jones C, Ghetie V, Vitetta ES. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res 2000;258:417–424.

    CAS  PubMed  Google Scholar 

  89. Rose TJ, Moreau L, Eckenberg R, Theze J. Structural Analysis and Modeling of a Synthetic Interleukin-2 Mimetic and Its Interleukin-2Rta2 Receptor J Biol. Chem 2003;278:22,868–22,876.

    Google Scholar 

  90. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability. J Natl Cancer Inst 2003;95:741–749.

    CAS  PubMed  Google Scholar 

  91. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL, Generation of lowtoxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood 2003;101:4853–4861.

    CAS  PubMed  Google Scholar 

  92. Eckenberg R, Rose T, Moreau JL, et al. The first alpha helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor beta chain, and induces lymphokine-activated killer cells. J Exp Med 2000;191:529–540.

    CAS  PubMed  Google Scholar 

  93. Cotran RS, Pober JS, Gimbrone Jr MA, et al. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988; 140:1883–1888.

    CAS  PubMed  Google Scholar 

  94. Pober JS. Cytokine-mediated activation of vascular endothelium. Am J Pathol 1988;133:426–433.

    CAS  PubMed  Google Scholar 

  95. Lentsch AB, Miller FN, Edwards MJ. Mechanisms of leukocyte-mediated tissue injury induced by interleukin 2. Cancer Immunol Immunother 1999;47: 243–248.

    CAS  PubMed  Google Scholar 

  96. Damle NK, Doyle LV. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J Immunol 1989; 142: 2660–2669.

    CAS  PubMed  Google Scholar 

  97. Edwards MJ, Abney DL, Miller FN. Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity. Surgery 1999; 110:199–204

    Google Scholar 

  98. Elliott MJ, Finn AH. Interaction between neutrophils and endothelium. Ann Thorac Surg 1993;56:1503–1508.

    CAS  PubMed  Google Scholar 

  99. Stevens P, Piazza DE. Interleukin-2 increases the oxidative activity and induces migration of murine polymorphonuclear leukocytes in vivo. Int J Immunopharmacol 1990; 12:605–611.

    CAS  PubMed  Google Scholar 

  100. Saba TM. Kinetics of plasma fibronectin: Relationship to phagocytic function and lung vascular integrity. In: Mosher DF, ed. Fibronectin. San Diego, CA: Academic Press; 1989, pp. 395–439.

    Google Scholar 

  101. Welbourn R, Goldman G, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann Surg 1990;212:728–733.

    CAS  PubMed  Google Scholar 

  102. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, Jacob HS. Lymphokine activated killer (LAK) cell-mediated endothelial injury: A mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2. Trans Assoc Am Phys 1987; 100:21–27.

    CAS  PubMed  Google Scholar 

  103. Kotasek D, Vercellotti GM, Ochoa AC, Bach FH, White JG, Jacob HS. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res 1988;48:5528–5532.

    CAS  PubMed  Google Scholar 

  104. Anderson TD, Hayes TJ, Gately MK, Bontempo JM, Stern LL, Truitt GA. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab Invest 1988;59:598–612.

    CAS  PubMed  Google Scholar 

  105. Bechard DE, Fairman RP, Hinshaw DB, Fowler AA, Glauser FL. In vivo interleukin-2 activated sheep lung lymph lymphocytes increase ovine vascular endothelial permeability by non-lytic mechanisms. Eur J Cancer 1990;26:1074–1078.

    CAS  PubMed  Google Scholar 

  106. Assier EV, Jullien J, Lefort J, et al. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J Immunol 2004; 172:7661–7668.

    CAS  PubMed  Google Scholar 

  107. Lehmann PV, Schumm G, Moon D, et al. Acute lethal graft-versus-host reaction induced by major histocompatibility complex class II-reactive T-helper cell clones. J Exp Med 1990;171:1485–1496.

    CAS  PubMed  Google Scholar 

  108. van Hinsbergh VW, van Nieuw Amerongen GP. Endothelial hyperpermeability in vascular leakage. Vascul Pharmacol 2002;39:171–172.

    PubMed  Google Scholar 

  109. Kaslovsky RA, Lai L, Parker K, Malik AB. Mediation of endothelial injury following neutrophil adherence to extracellular matrix. Am J Physiol 1993; 264:L401–L405.

    CAS  PubMed  Google Scholar 

  110. Mustafa A, McKallip RJ, Fisher M, Duncan R, Nagarkatti PS, Nagarkatti M. Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. J Immunother 2002; 25:476–488.

    CAS  PubMed  Google Scholar 

  111. Rafi-Janajreh AQ, Chen D, Schmits R, et al. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J Immunol 1999;163:1619–1627.

    CAS  PubMed  Google Scholar 

  112. Carsuzaa F. Pierre C. Morand JJ. Farnarier C. Marrot F. Kaplanski G. Capillary leak syndrome disclosing Ofuji’s papuloerythroderma. Ann Dermatol Venereol 1996; 123:559–562.

    CAS  PubMed  Google Scholar 

  113. Baluna R, Sausville EA, Stone M, Stetler-Stevenson MA, Uhr J, Vitetta ES. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A-chain-containing immunotoxins. Clin Cancer Res 1996;2:1705–1712.

    CAS  PubMed  Google Scholar 

  114. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427–451.

    CAS  PubMed  Google Scholar 

  115. Baars JW, De Boer JP, Wagstaff J, et al. Interleukin-2 induces activation of coagulation and fibrinolysis: Resemblance to the changes seen during experimental endotoxaemia. Br J Haematol 1992;88:295–301.

    Google Scholar 

  116. Deehan DJ, Heys SD, Simpson W, Herriot R, Broom J, Eremin O. Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol 1994;95:366–372.

    CAS  PubMed  Google Scholar 

  117. Dubinett SM, Huang M, Lichtenstein A, et al. Tumor necrosis factor-plays a central role in interleukin-2-induced pulmonary vascular leak and lymphocyte accumulation. Cell Immunol 1994;157:170–180.

    CAS  PubMed  Google Scholar 

  118. Zhang J, Yu ZX, Hilbert SL, Yamaguchi, M, Chadwick DP. Cardiotoxicity of human recombinant interleukin-2 in rats. A morphological study. Circulation 1993;87:1340–1353.

    CAS  PubMed  Google Scholar 

  119. Edwards MJ, Abney DL, Heniford BT, Miller FN. Passive immunization against tumor necrosis factor inhibits IL-2-induced microvascular alterations and reduces toxicity. Surgery 1992; 112:480–486.

    CAS  PubMed  Google Scholar 

  120. Wheatley EM, Vincent PA, McKeown-Longo PJ, Saba TM. Effect of fibronectin on permeability of normal and TNF-treated lung endothelial cell monolayers. Am J Physiol 1993;264:R90–R96.

    CAS  PubMed  Google Scholar 

  121. Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB. Induction of endothelial cell apoptosis by TNF: modulation by inhibitors of protein synthesis. Exp Cell Res 1994;214:584–594.

    CAS  PubMed  Google Scholar 

  122. Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, Al. J Biol Chem 1996;271:27,201–27,204.

    CAS  PubMed  Google Scholar 

  123. Thijs LG, Hack CE, Strack Van Schijndel RJM, et al. Activation of the complement system during immunotherapy with recombinant IL-2. J Immunol 1990; 144:2419–2424.

    CAS  PubMed  Google Scholar 

  124. Puri RK, Rosenberg SA. Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice. Cancer Immunol Immunother 1989;28:267–274.

    CAS  PubMed  Google Scholar 

  125. Alon R, Cahalon L, Hershkoviz R, et al. TNF-α binds to the N-terminal domain of fibronectin and augments the beta1-integrin-mediated adhesion of CD4+ T-lymphocytes to the glycoprotein. J Immunol 1994; 152:1309–1313.

    Google Scholar 

  126. Goldblum SE, Ding X, Campbell-Washington J. TNF-a induces endothelial cell F-actin depolymerization, new actin synthesis, and barrier dysfunction. Am J Physiol Cell Physiol 1993;264:C894–C905.

    CAS  Google Scholar 

  127. Locker GJ, Kofler J, Stoiser B, et al. Relation of pro-and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2. Eur Cytokine Network 2000; 11:391–396.

    CAS  Google Scholar 

  128. Dudek, SM, Garcia JGN. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001;91:1487–1500.

    CAS  PubMed  Google Scholar 

  129. Fujita S, Puri R, Yu ZX, Travis W, Yamaguchi M, Ferrans VJ. Interleukin-1 alpha reduces the severity of the vascular leak syndrome produced by interleukin-2 and interleukin-2 plus interferon-alpha. Toxicol Pathol 1994;22:381–397.

    CAS  PubMed  Google Scholar 

  130. Puri RK, Travis WD, Rosenberg SA. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Cancer Res 1989;49:969–976.

    CAS  PubMed  Google Scholar 

  131. Thom AK, Fraker DL, Norton JA. IL-1 receptor antagonist (IL-Ira) augments IL-2-induced pulmonary vascular leak. J Surg Res 1993;54:336–341.

    CAS  PubMed  Google Scholar 

  132. Cavender DE, Edelbaum D. Inhibition by IL-1 of endothelial cell activation induced by tumor necrosis factor or lymphotoxin. J Immunol 1988; 141:3111–3116.

    CAS  PubMed  Google Scholar 

  133. Yamaguchi Y, Suda T, Shiozaki H, Miura Y, Hitoshi Y, Tominaga A, Takatsu K, Kasahara T. Role of IL-5 in IL-2-induced eosinophilia. J Immunol 1990;145:873–877.

    CAS  PubMed  Google Scholar 

  134. Gimbrone MA Jr, Obin MS, Brock AF, et al. Endothelial interleukin-8: A novel inhibitor of leukocyte-endothelial interactions. Science 1989;246: 1601–1603.

    CAS  PubMed  Google Scholar 

  135. Westlin W, Gimbrone MA. Neutrophil-mediated damage to human vascular endothelium. Am J Pathol 1993; 142:117–128.

    CAS  PubMed  Google Scholar 

  136. Luscinskas FW, Kiely JM, Ding H, Obin MS, Hebert CA, Baker JB, Gimbrone MA. In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophil-endothelial adhesive interactions. J Immunol 1992;149:2163–2171.

    CAS  PubMed  Google Scholar 

  137. Hechman DH, Cybulsky MI, Fuchs HJ, Baker JB, Gimbrone Jr. MA. Intra-vascular IL-8, Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol 1991;147:883–892.

    Google Scholar 

  138. Finn A, Naik S, Klein N, Levinsky RJ, Strobel S, Elliott M. Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;105:234–241.

    CAS  PubMed  Google Scholar 

  139. Li L, Elliott JF, Mosmann, TR. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J Immunol 1994;153:3967–3978.

    CAS  PubMed  Google Scholar 

  140. Westin WF, Kiely J, Gimbrone MA. Interleukin-8 induces changes in human neutrophil actin conformation and distribution: Relationship to inhibiton of adhesion to cytokine-activated endothelium. J Leukoc Biol 1992;52:43–51.

    Google Scholar 

  141. Lentsch AB, Edwards MJ, Sims DE, Nakagawa K, Wellhausen SR, Miller FN. Interleukin-10 inhibits interleukin-2-induced tumor necrosis factor production but does not reduce toxicity in C3H/HeN mice. J Leukoc Biol 1996; 60:51–57.

    CAS  PubMed  Google Scholar 

  142. Heniford BT, Edwards MJ, Wilson MA, Klar EA, Doak KW, Miller FN. Interleukin-8 suppresses the toxicity and antitumor effect of interleukin-2. J Surg Res 1994;56:82–88.

    CAS  PubMed  Google Scholar 

  143. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophaage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995; 155:2222–2229.

    CAS  PubMed  Google Scholar 

  144. Okamoto M, Kato S, Oizumi K, et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 2002;99:1289–1298.

    CAS  PubMed  Google Scholar 

  145. Stolpen AH, Guinan EC, Fiers W, Pober JS. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 1986:123:16–24.

    CAS  PubMed  Google Scholar 

  146. Gao B, Curtis T, Blumenstock F, Minnear F, Saba T. Increased recycling of (alpha) 5 (beta) 1 integrins by lung endothelial cells in response to tumor necrosis factor. J Cell Sci 2000;113:247–257.

    CAS  PubMed  Google Scholar 

  147. Ferrero E, Villa A, Ferrero ME, et al. Tumor necrosis factor a-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996;56:3211–3215.

    CAS  PubMed  Google Scholar 

  148. Groeneveld JA. Vascular pharmacology of acute lung injury and acute respiratory distress syndrome Vasc Pharmacol 2002;39:247–256.

    CAS  Google Scholar 

  149. Rondeau E, Sraer J, Bens M, Doleris LM, Lacave R, Sraer JD. Production of 5-lipoxygenase pathway metabolites by peripheral leucocytes in capillary leak syndrome (Clarkson disease). Eur J Clin Invest 1987; 17:53–57.

    CAS  PubMed  Google Scholar 

  150. Cahill RA, Zhao Y, Murphy R, Sala A, Foegh M, Spitzer T, Deeg HJ. High urinary leukotriene E4 (LTE4) and thromboxane 2 (TXB2) levels are associated with capillary leak syndrome in bone marrow transplant patients. Adv Prostaglandin Thromboxane Leukoc Res 1991;21B:525–528.

    CAS  Google Scholar 

  151. Welbourn R, Goldman G, Kobzik L, Paterson I, Shepro D, Hechtman HB. Interleukin-2 induces early multisystem organ edema mediated by neutrophils. Ann Surg 1991;214:181–186.

    CAS  PubMed  Google Scholar 

  152. Klausner JM, Goldman G, Skornick Y, et al. Interleukin-2-induced lung permeability is mediated by leukotriene B4. Cancer 66; 1990:2357–2364.

    CAS  PubMed  Google Scholar 

  153. Thijs LG, Hack CE, Strack van Schijndel RJM, et al. Activation of the complement system during immunotherapy with interleukin-2: relation to the development of side effects. J Immunol 1990; 144:2419–2424.

    CAS  PubMed  Google Scholar 

  154. Nurnberger W, Michelmann I, Petrik K, et al. Activity of Cl esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann Hematol 1993;67:17–21.

    CAS  PubMed  Google Scholar 

  155. Salat C, Holler E, Schleuning M, et al. Levels of the terminal complement complex, C3a-desArg and Cl-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation. Ann Hematol 1995;71: 271–274.

    CAS  PubMed  Google Scholar 

  156. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJ, Wagstaff J, Thijs LG. Clinhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993; 19: S19–S28.

    PubMed  Google Scholar 

  157. Marath A, Man W, Taylor KM. Histamine release in pediatrie cardiopulmonary bypass: a possible role in the capillary leak syndrome. Agents Actions 1987;20:299–302.

    CAS  PubMed  Google Scholar 

  158. Edwards MJ, Heniford BT, Miller FN. Mast cell degranulation inhibits IL-2-induced microvascular protein leakage. J Surg Res 1992;52:429–435.

    CAS  PubMed  Google Scholar 

  159. DeFouw DO, Brown KL, Feinberg RN. Canine jugular vein endothelial cell monolayers in vitro: vasomediator-activated diffusive albumin pathway. J Vase Res 1993;30:154–160.

    CAS  Google Scholar 

  160. Hinshaw DB, Burger JM, Beals TF, Armstrong BC, Hyslop PA. Actin polymerization in cellular oxidant injury. Arch Biochem Biophys 1991;288:311–316.

    CAS  PubMed  Google Scholar 

  161. Thurston G, Baldwin AL, Wilson LM. Changes in endothelial actin cytoskeleton at leakage sites in the rat mesenteric microvasculature. Am J Physiol 1995;268:H316–H329.

    CAS  PubMed  Google Scholar 

  162. Gottlieb AI, Langille BL, Wong MK, Kim DW. Structure and function of the endothelial cytoskeleton. Lab Invest 1991;65:123–137.

    CAS  PubMed  Google Scholar 

  163. Klausner JM, Paterson IS, Goldman G, et al. Interleukin-2-induced lung injury is mediated by oxygen free radicals. Surgery 1991;109:169–175.

    CAS  PubMed  Google Scholar 

  164. Goldman G, Welbourn R, Alexander S, et al. Modulation of pulmonary permeability in vivo with agents that affect the cytoskeleton. Surgery 1991;109: 533–538.

    CAS  PubMed  Google Scholar 

  165. Baars JW, Wolbink GJ, Hart MH, et al. The release of interleukin-8 during intravenous bolus treatment with interleukin-2. Ann Oncol 1994;5:929–934.

    CAS  PubMed  Google Scholar 

  166. Hack CE, Wagstaff J, Strack van Schijndel RJ, et al. Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: Implications for septic shock. Thromb Haemost 1991;65:497–503.

    CAS  PubMed  Google Scholar 

  167. Suschek C, Rothe H, Fehsel K, Enczmann J, Kolb-Bachofen V. Induction of a macrophagea-like nitric oxide synthase in cultured rat aortic endothelial cells. IL-1 beta-mediated induction regulated by tumor necrosis factor-alpha and IFN-gamma. J Immunol 1990;151:3283–3291.

    Google Scholar 

  168. Mulvin DW, Grosso MA, Kruse CA, Howard RB, Repine JE, Johnston MR. The role of toxic oxygen metabolites in interleukin-2-induced vascular leak syndrome. Curr Surg 1989;46:396–398.

    CAS  PubMed  Google Scholar 

  169. Kilbourn RG, Fonseca GA, Griffith OW, et al. NG-methyl-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 1995;23:1018–1024.

    CAS  PubMed  Google Scholar 

  170. Orucevic A, Lala PK. N-G-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin-2-induced capillary leak syndrome in healthy mice. J Immunother 1995;18:210–220.

    CAS  Google Scholar 

  171. Leder GH, Oppenheim M, Rosenstein M, et al. Inhibition of nitric oxide synthesis does not improve interleukin-2-mediated antitumor effects in vivo. Eur Surg Res 1996;28:167–178.

    CAS  PubMed  Google Scholar 

  172. Locker GJ, Kapiotis S, Veitl M, et al. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br J Haematol 1999;105:912–919.

    CAS  PubMed  Google Scholar 

  173. Velanovich V. Crystalloid versus colloid fluid resuscitation: A meta-analysis of mortality. Surgery 1989;105:65–71.

    CAS  PubMed  Google Scholar 

  174. Pockaj BA, Yang JC, Lotze MT, et al. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. J. Immunother. 1994;15: 22–28.

    CAS  Google Scholar 

  175. Memoli B, De Nicola L, Libetta C, et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Am J Kidney Dis 1995;26:27–33.

    CAS  PubMed  Google Scholar 

  176. Hasibeder WR. Fluid resuscitation during capillary leakage: does the type of fluid make a difference. Intensive Care Med 2002;28:532–534.

    PubMed  Google Scholar 

  177. Marx G. Fluid therapy in sepsis with capillary leakage. Eur J Anaesthesiol 2003;20:429–442.

    CAS  PubMed  Google Scholar 

  178. Koepp A. Lampert R. Use of plasmapheresis in a 62-year-old patient with severe infection. Infusionstherapie und Transfusionsmedizin. 1996;23:92–96.

    CAS  PubMed  Google Scholar 

  179. Edwards MJ, Heniford BT, Klar EA, Doak KW, Miller FN. Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest 1992;90:637–641.

    CAS  PubMed  Google Scholar 

  180. Kovach NL, Lindgren CG, Fefer A, Thompson JA, Yednock T, Harlan JM. Pentoxifylline inhibits integrin-mediated adherence of interleukin-2-activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components and cultured tumor cells. Blood 1994;84:2234–2242.

    CAS  PubMed  Google Scholar 

  181. Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 1994;54:3436–3441.

    CAS  PubMed  Google Scholar 

  182. Kemeny MM, Botchkina GI, Ochani M, Bianchi M, Urmacher C, Tracey KJ. The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Proc Natl Acad Sci USA 1998:95:4561–4566.

    CAS  PubMed  Google Scholar 

  183. Abdih H, Kelly CJ, Bouchier-Hayes D, Barry M, Kearns S. Taurine prevents interleukin-2-induced acute lung injury in rats. Eur Surg Res 2000;32:347–352.

    CAS  PubMed  Google Scholar 

  184. Staak JO, Glossmann JP, Esser JM, Diehl V, Mietz H, Josting A. Thalidomide for systemic capillary leak syndrome. Am J Med 2003;115:332–334.

    PubMed  Google Scholar 

  185. Dhingra VK, Uusaro A, Holmes CL, Walley KR. Attenuation of lung inflammation by adrenergic agonist in murine acute lung injury. Anesthesiology 2001;95:947–953.

    CAS  PubMed  Google Scholar 

  186. Butler LD, Mohler KM, Layman NK, Cain RL, Riedl PE, Puckett LD, Bendele AM. Interleukine-2 induced systemic toxicity: Induction of mediators and immunopharmacologic intervention. Immunopharmacol Immunotoxicol 1989; 11:445–487.

    CAS  PubMed  Google Scholar 

  187. Mier JW, Aronson FR, Numerof RP, Vachino G, Atkins MB. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res 1988;7:459–476.

    CAS  PubMed  Google Scholar 

  188. DeJoy SQ, Jeyaseelan, R Sr, Torley LW, Schow SR, Wick MM, Kerwar SS, Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate. Cancer Res 1995;55:4929–4935.

    CAS  PubMed  Google Scholar 

  189. Hack CE, Ogilvie AC, Eisele B, Jansen PM, Wagstaaff J, Thijs LG. Initial studies on the administration of Cl-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 1994;388:335–357.

    CAS  PubMed  Google Scholar 

  190. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. Clesterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000;52:91–112.

    CAS  PubMed  Google Scholar 

  191. Ohkubo C, Bigos D, Jain RK. Interleukin 2 induced leukocyte adhesion to the normal and tumor microvascular endothelium in vivo and its inhibition by dextran sulfate: Implications for vascular leak syndrome. Cancer Res 1991;51: 1561–1563.

    CAS  PubMed  Google Scholar 

  192. McKallip RJ, Fisher M, Do Y, et al. Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem 2003;278:43,818–43,830.

    CAS  PubMed  Google Scholar 

  193. Palmer PA, Atzpodien J, Philip T, et al. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother 1993;8:123–136.

    CAS  PubMed  Google Scholar 

  194. Guida M, Abbate I, Casamassima A, et al. Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications. Cancer Biother 1995;10:195–203.

    CAS  PubMed  Google Scholar 

  195. Huland E, Heinzer H, Mir TS, Huland H. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. Cancer J Sci Am 1997;3(Suppl 1):S98–S105.

    PubMed  Google Scholar 

  196. Anderson PM. Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 1994;27:19–31.

    CAS  PubMed  Google Scholar 

  197. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Huntington) 2002; 16(Suppl 13): 11–20.

    Google Scholar 

  198. Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994;73:824–831.

    CAS  PubMed  Google Scholar 

  199. Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors. Clin Cancer Res 1999;5:51–60

    CAS  PubMed  Google Scholar 

  200. Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extra-cellular matrix. Blood 2002;99:1659–1665.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Cancer Therapy and Research Center, San Antonio, TX

    Roxana G. Baluna

Authors
  1. Roxana G. Baluna
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. DyPort Vaccine Company, LLC, Frederick, MD

    Robert V. House

  2. Poison Center and Pharmacovigilance Unit, Lyon Cedex, France

    Jacques Descotes

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Baluna, R.G. (2007). Cytokine-Induced Vascular Leak Syndrome. In: House, R.V., Descotes, J. (eds) Cytokines in Human Health. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-350-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-350-9_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-467-8

  • Online ISBN: 978-1-59745-350-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation